Universal bispecific antibody for targeting tumor cells for destruction by cytotoxic T cells.

Universal bispecific antibody for targeting tumor cells for destruction by cytotoxic T cells.

Previous studies have demonstrated that bispecific hybrid antibodies produced by cell-cell fusion or chemically conjugated heteroaggregates can direct cytotoxic T lymphocytes to kill target cells for which they have no intrinsic specificity, a phenomenon we call effector cell retargeting (ECR). Thes...

Descrizione completa

Dettagli Bibliografici
Autori principali:	Gilliland, L, Clark, MR, Waldmann, H
Natura:	Journal article
Lingua:	English
Pubblicazione:	1988

Documenti analoghi

T-cell killing of target cells induced by hybrid antibodies: comparison of two bispecific monoclonal antibodies.
di: Clark, MR, et al.
Pubblicazione: (1987)

Development of humanized bispecific antibodies reactive with cytotoxic lymphocytes and tumor cells overexpressing the HER2 protooncogene.
di: Shalaby, MR, et al.
Pubblicazione: (1992)

Oncolytic adenovirus expressing bispecific antibody targets T‐cell cytotoxicity in cancer biopsies
di: Freedman, J, et al.
Pubblicazione: (2017)

Oncolytic adenovirus expressing bispecific antibody targets T‐cell cytotoxicity in cancer biopsies
di: Joshua D Freedman, et al.
Pubblicazione: (2017-06-01)

Bispecific antibody-activated T cells enhance NK cell-mediated antibody-dependent cellular cytotoxicity
di: Zhaoming Wang, et al.
Pubblicazione: (2021-12-01)

THE POTENTIAL OF HYBRID ANTIBODIES SECRETED BY HYBRID-HYBRIDOMAS IN TUMOR-THERAPY
di: Clark, M, et al.
Pubblicazione: (1987)

The role of calcium in the destruction of target cells by cytotoxic T cells
di: Allbritton, Nancy L. (Nancy Lynn)
Pubblicazione: (2005)

Safety Profiling of Tumor-targeted T Cell–Bispecific Antibodies with Alveolus Lung- and Colon-on-Chip
di: S. Kerns, et al.
Pubblicazione: (2023-01-01)

Harnessing the cytotoxic granule exocytosis to augment the efficacy of T-cell-engaging bispecific antibody therapy
di: Mika Casey, et al.
Pubblicazione: (2024-01-01)

697 Tumor-targeted CD28 costimulatory bispecific antibodies enhance T cell activation in solid tumors
di: Gregory Moore, et al.
Pubblicazione: (2020-11-01)

Bispecific antibody-targeted T-cell therapy for acute myeloid leukemia
di: Ewa Kubicka, et al.
Pubblicazione: (2022-11-01)

Therapeutic Bispecific T-Cell Engager Antibody Targeting the Transferrin Receptor
di: Mingpeng Fu, et al.
Pubblicazione: (2019-06-01)

Characterization of a novel bispecific antibody targeting tissue factor-positive tumors with T cell engagement
di: Zhidi Pan, et al.
Pubblicazione: (2022-04-01)

Development of a bispecific antibody targeting PD-L1 and TIGIT with optimal cytotoxicity
di: Zhenwei Zhong, et al.
Pubblicazione: (2022-10-01)

Targeting tumor vasculature to improve antitumor activity of T cells armed ex vivo with T cell engaging bispecific antibody
di: Madelyn Espinosa-Cotton, et al.
Pubblicazione: (2023-03-01)

Human immunocompetent Organ-on-Chip platforms allow safety profiling of tumor-targeted T-cell bispecific antibodies
di: S Jordan Kerns, et al.
Pubblicazione: (2021-08-01)

Therapeutic potential of rat monoclonal antibodies: isotype specificity of antibody-dependent cell-mediated cytotoxicity with human lymphocytes.
di: Hale, G, et al.
Pubblicazione: (1985)

Comparative Analysis of Bispecific Antibody and Streptavidin-Targeted Radioimmunotherapy for B-cell Cancers
di: Green, Damian J., et al.
Pubblicazione: (2020)

Editorial: Bispecific Antibodies for T-Cell Based Immunotherapy
di: Brian H. Santich, et al.
Pubblicazione: (2020-12-01)

Hybrid antibodies for therapy.
di: Clark, M, et al.
Pubblicazione: (1988)

Bispecific, T-Cell-Recruiting Antibodies in B-Cell Malignancies
di: Margaux Lejeune, et al.
Pubblicazione: (2020-05-01)

Bispecific antibodies in indolent B-cell lymphomas
di: Vivek S. Radhakrishnan, et al.
Pubblicazione: (2024-01-01)

Targeting T cells with tetravalent bispecific antibodies for the treatment of graft-versus-host disease
di: Madelyn Espinosa-Cotton, et al.
Pubblicazione: (2025-01-01)

Recent advances of bispecific antibodies in solid tumors
di: Shengnan Yu, et al.
Pubblicazione: (2017-09-01)

Bispecific T cell engager (BiTE®) antibody constructs can mediate bystander tumor cell killing.
di: Sandra L Ross, et al.
Pubblicazione: (2017-01-01)

Modulating tumor infiltrating myeloid cells to enhance bispecific antibody-driven T cell infiltration and anti-tumor response
di: Jeong A. Park, et al.
Pubblicazione: (2021-09-01)

Engineering of dendritic cell bispecific extracellular vesicles for tumor-targeting immunotherapy
di: Fang Xu, et al.
Pubblicazione: (2023-10-01)

Dual Targeting of Tumor Cells with Bispecific Single-Chain Fv-Immunoliposomes
di: Katharina Mack, et al.
Pubblicazione: (2012-07-01)

Co-targeting cancer stem-like cells and bulk cancer cells with a bispecific antibody
di: Shi Hu
Pubblicazione: (2017-05-01)

Bispecific antibody targets and therapies in multiple myeloma
di: Matthew Rees, et al.
Pubblicazione: (2024-10-01)

Dual-target Bridging ELISA for Bispecific Antibodies
di: Min Pei, et al.
Pubblicazione: (2022-10-01)

T-cell stimulating vaccines empower CD3 bispecific antibody therapy in solid tumors
di: Jim Middelburg, et al.
Pubblicazione: (2024-01-01)

A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells
di: Shengnan Yu, et al.
Pubblicazione: (2019-08-01)

Blocking of cytotoxic T cell function by monoclonal antibodies against the CD45 antigen (T200/leukocyte-common antigen).
di: Tighe, H, et al.
Pubblicazione: (1987)

Src/lck inhibitor dasatinib reversibly switches off cytokine release and T cell cytotoxicity following stimulation with T cell bispecific antibodies
di: Christian Klein, et al.
Pubblicazione: (2021-07-01)

698 PD-L1 targeted CD28 costimulatory bispecific antibodies enhance T cell activation in solid tumors
di: Jing Qi, et al.
Pubblicazione: (2021-11-01)

Engineering a tumor-selective prodrug T-cell engager bispecific antibody for safer immunotherapy
di: Amelia C. McCue, et al.
Pubblicazione: (2024-12-01)

Overcoming tumor heterogeneity by ex vivo arming of T cells using multiple bispecific antibodies
di: Nai-Kong V Cheung, et al.
Pubblicazione: (2022-01-01)

A Novel T Cell-Engaging Bispecific Antibody for Treating Mesothelin-Positive Solid Tumors
di: Aerin Yoon, et al.
Pubblicazione: (2020-03-01)

The potential of hybrid antibodies secreted by hybrid-hybridomas in tumour therapy.
di: Clark, M, et al.
Pubblicazione: (1988)